Last reviewed · How we verify
NCT01170806
Study of Pharmacodynamic Equivalence of Two Commercial Formulations of Orlistat (Lipiblock vs Xenical) on Intestinal Lipases Inhibition
NA trial testing Orlistat in Obesity in 20 participants. Completed in 1 April 2010.
1 March 2010
Quick facts
| Lead sponsor | University of Campinas, Brazil |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 1 October 2009 |
| Primary completion | 1 March 2010 |
| Estimated completion | 1 April 2010 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Orlistat — full drug profile →
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
University of Campinas, Brazil
Who can join
Adults 18 to 45, female only, with Obesity. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Study of equivalence between two commercial capsules of Orlistat on fat absorption inhibition
Time frame: baseline
This study aim to investigate differences in fat absorption inhibition after 7 days treatment with Lipiblock and Xenical (two commercial capsules of Orlistat). Therefore, total fecal fat and fecal fat percentage wil be analysed, comparing these data before and after treatment with Lipiblock and Xeical.
Sponsor's own description
Obesity is a chronic condition with fat-rich diets playing a major role in its etiology. Pharmacological therapy has been proposed for weight loss and maintenance. This study aims to study the intestinal lipase blockade by partial inhibition of fat absorption after treatment with two commercials formulations of Orlistat.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01170806
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Orlistat
Trials testing the same drug.
- NCT06854614 — Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic · Phase 4 · active not recruiting
- NCT05816343 — Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia · Phase 2 · recruiting
- NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
- NCT05579249 — A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America · Phase 4 · completed
- NCT05496075 — Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia · Phase 4 · completed
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other University of Campinas, Brazil trials
Trials by the same sponsor.
- NCT06929676 — Assessment of Tooth Mobility After Non-surgical Periodontal Treatment Followed by Tooth Splinting · NA · enrolling by invitation
- NCT07456163 — Influence of Zirconia Abutments on Peri-Implant Tissues in Single-Tooth Restorations · NA · recruiting
- NCT06884475 — Evaluation of Implantoplasty in the Treatment of Peri-Implantitis. · NA · active not recruiting
- NCT06450327 — Resistant Hypertension An Open, Complicated ("Cum Plicare") or Complex ("Cum Plexus") Syndrome? · recruiting
- NCT06600867 — Method for Measuring Dental Mobility and Displacement Force · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01170806 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Campinas, Brazil
- Last refreshed: 28 January 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01170806.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing